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between 1997 and 2006 was conducted. Elderly patients with
continuous health plan coverage,  drug prescription per calen-
dar year, and  diagnosis for 1) asthma; 2) cancer; or 3) cardio-
vascular disease (CVD) were selected. Drug vintage, deﬁned as
the ingredient’s earliest marketed date, was drawn from Health
Canada Drug Product Database. A multivariate analysis was
conducted to estimate the impact of drug vintage on patients’
probability of dying using time-varying Cox proportional hazard
model. The covariates used for adjustment in the regression
model were: demographics characteristics, guaranteed income
supplement (GIS) status, medical resources utilization, concomi-
tant drug utilization, and comorbidities. RESULTS: A total of
6912, 12,341, and 29,394 elderly subjects formed the asthma,
cancer, and CVD study populations, respectively, of which 1220
(18%), 3479 (28%), and 6043 (21%) died during the observa-
tion period. Overall, mean age was 68 years; 49% of subjects
were women. After controlling for confounding factors, the use
of recent medications (i.e. Post-1990 ingredients) was consis-
tently associated with a signiﬁcant risk reduction of mortality
(hazard ratios <1.0, p < 0.0001 for all disease areas), relative to
older ingredients, suggesting that recent drug innovation had a
signiﬁcant beneﬁcial impact on longevity in patients with asthma,
cancer, or CVD. Other covariates associated with an increased
risk of mortality included age, gender, GIS beneﬁciaries, hospi-
talization, and number of comorbidities. CONCLUSION: This
analysis showed that drug innovation, in particular medications
launched after 1990, had a signiﬁcant beneﬁcial impact on lon-
gevity of elderly patients in three important disease areas.
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OBJECTIVE: Safety, efﬁcacy, and ﬁnancial concerns are impor-
tant considerations when evaluating the reasons for market
discontinuation of drugs. In this study, market discontinuation
of new chemical entities (NCEs) approved by the FDA in the
period 1980–2007 were analyzed according to therapeutic class,
regulatory changes, orphan drug status, and priority review.
METHODS: Data was derived from the FDA, Micromedex and
Medline. A drug was considered discontinued if deleted from
the FDA’s Orange book. Withdrawals of approval were also
included in the study. Descriptive statistics and chi-square tests
were performed. RESULTS: A total of 703 NCEs were approved
during the study period. In December 31, 2007, 71.8% NCEs
remained in the market; 14.9% were discontinued; 5.4% NCES
had the brand discontinued, but the generic was available; 7.0%
had changes in route, dosage form or strength; and 0.9% were
over-the-counter drugs. Safety was the primary reason for with-
drawal of 30 (4.3%) NCEs; 14 (2.0%) NCEs had Federal Reg-
ister determination for not being discontinued for safety or
efﬁcacy reasons; and 61 (8.7%) had no reasons stated by the
FDA. Compared to other classes antibiotics were more likely
(p < 0.05) to be discontinued. Analyses of priority review, orphan
drug status, and the sponsor company’s country (US or non-US)
with respect to market withdrawal were not signiﬁcant. Com-
parisons of pharmaceuticals withdrawn due to safety reasons
with therapeutic class and implementation of Prescription Drug
User Fee Act were also not signiﬁcant. CONCLUSION: One in
seven NCEs approved during the study period were discontinued
from the market. A small percentage of drugs were discontinued
due to safety or ﬁnancial reasons. An ongoing evaluation of
NCEs in the market place is important to determine which prod-
ucts provide optimal beneﬁts in terms of efﬁcacy, safety, and
value compared to other products overall and other products
within the same therapeutic class.
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OBJECTIVE: The U.S. Medicare drug beneﬁt (Part D) was
implemented in January 2006 to reduce cost-related underuse of
medications, experienced by 25% of older patients in the US.
This study evaluated the impact of Part D on medication use
patterns and cost-savings for subsequent medical services.
METHODS: We collected all claims of 20,645 members from a
large Medicare managed care plan between January 1, 2005 and
December 31, 2006. We used a time series and comparison group
design to measure the changes in outcomes before and after Part
D. Intervention group included members who had no drug cov-
erage or quarterly caps in drug spending and whose coverage
became more generous after Part D. The comparison group had
no limits on drug spending before and after Part D. We estimated
the impact of Part D on 1) out-of-pocket pharmacy spending and
non-drug medical spending using generalized linear models;
2) number of monthly drug scripts, medication adherence, and
counts of hospitalization and ED visits using Poisson regressions;
and 3) adherence for antihypertensive, lipid-lowering, anti-
diabetic, and antipsychotic agents using generalized-estimating-
equation models. RESULTS: Part D reduced out-of-pocket
expenditures by 20%–50% depending on members’ drug limits.
Part D increased number of monthly drug scripts by 0.5, among
members without drug coverage who prescribed 3 scripts per
month and members with quarterly $150 cap who prescribed
about 3.5 monthly scripts in 2005. We did not ﬁnd improve-
ments on medication adherence for selected drug classes. We
found total medical and inpatient spending reduced by 10% (not
statistically signiﬁcant) for members who had a previous $625
quarterly cap. We did not ﬁnd any cost offsets for members with
other drug limits. CONCLUSION: Part D decreased out-of-
pocket pharmacy expenditures and increased demand for drugs
but did not induce savings from subsequent medical services.
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OBJECTIVE: Since the implementation of Medicare Part D,
numerous anecdotal descriptions and a few small studies have
reported low reimbursements to community pharmacies. The
purpose of this study was to quantitatively assess the impact of
Medicare Part D on percent gross margin earned by independent
pharmacies in Texas using prescription claims data collected by a
pharmacy claims switching company for dual eligible beneﬁcia-
ries. METHODS: The study evaluated a total of 457,611 claims
for prescriptions dispensed in the fourth quarter of 2005
(n = 152,521) and the second and third quarters of 2006
(n = 305,090). The prescriptions were dispensed by 313 indepen-
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